Vascular-targeted photodynamic therapy for prostate cancer Book Section
| Authors: | Wong, N. C.; Scherz, A.; Coleman, J. A.; Murray, K. S. |
| Editors: | Rastinehad, A. R.; Siegel, D. N.; Wood, B. J.; McClure, T. |
| Article/Chapter Title: | Vascular-targeted photodynamic therapy for prostate cancer |
| Abstract: | Vascular-targeted photodynamic therapy (VTP) is an approved focal treatment for prostate cancer which is minimally invasive and performed in the ambulatory setting. VTP is administered using a photosensitizer that is delivered intravenously and activated locally by laser fibers that emit a specific wavelength of light. Once activated, the photosensitizer generates free radicals, causing a severe form of uniform local vascular injury within tissues, resulting in a controlled, non-thermal form of coagulative tissue necrosis that is tumoricidal and associated with minimal side effects or collateral tissue damage. The development of prostate cancer VTP has rapidly advanced over the past few decades, with a maturing body of evidence supporting its clinical utility and adoptability to a number of relevant applications (Scherz et al., Vascular-targeted photodynamic therapy in prostate cancer: From bench to clinic. In: Kostron H, Hasan T, editors. Photodynamic medicine: from bench to clinic. Cambridge: Royal Society of Chemistry:461–480, 2016). In 2017, the European Medicines Agency approved VTP with WST-11 (Padeliporfin, TOOKAD Soluble; Steba Biotech S.A.) for the treatment of men with low-risk prostate cancer based on results from a phase III randomized controlled trial (Azzouzi et al., Lancet Oncol. 18(2):181–91, 2017; Gill et al., J Urol. 200(4):786–793, 2018). Additional trials are underway investigating treatment for men with intermediate-risk prostate cancer, including phase II trials in the USA (NCT03315754). The strong supporting evidence from clinical trials and preclinical studies with VTP demonstrates the significant potential of this therapy as a mainstay treatment for prostate cancer focal therapy. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021. |
| Keywords: | focal therapy; photodynamic; vtp; padeliporfin; prostate gland ablation; tookad soluble; wst-11 |
| Book Title: | Interventional Urology. 2nd ed |
| ISBN: | 978-3-030-73564-7 |
| Publisher: | Springer |
| Publication Place: | Cham, Switzerland |
| Date Published: | 2021-01-01 |
| Start Page: | 249 |
| End Page: | 255 |
| Language: | English |
| DOI: | 10.1007/978-3-030-73565-4_17 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book chapter: 17 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work